Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company, announced the acquisition of a portfolio of dopamine agonist drug combinations from Chase Therapeutics Corporation. This includes ALTO-207, formerly known as CTC-501, aimed at treating treatment-resistant depression $(TRD.UK)$. The acquisition aligns with Alto's mission to innovate in psychiatry by advancing ALTO-207, which combines pramipexole and ondansetron to deliver rapid antidepressant effects while minimizing adverse events. Alto plans to leverage its proprietary insights on dopamine biomarkers to further develop this promising treatment, with a Phase 2b trial anticipated by mid-2026. The transaction supports Alto's strategic expansion without altering its cash runway guidance into 2028.